Arch Biopartners Inc. announced the appointment of Dr. Patrick Vink as Chairman of the Company?s Board of Directors, effective January 15, 2026. Dr. Vink, M.D., M.B.A., has been an advisor to the pharmaceutical industry since 2015 and has served as a non-executive board member or chair of several public and private companies in North America and Europe. He has overseen or supported several transactions in these roles, including Bruker Corporation?s majority-ownership investment in Biognosys AG in 2023, and Chiesi Farmaceutici?s acquisition of Amryt Pharma later the same year.
Dr. Vink previously served as Executive Vice President and Chief Operating Officer of Cubist Pharmaceuticals Inc., overseeing global commercial and technical operations until its $9.5 billion acquisition by Merck in 2015. Prior to Cubist, he was Senior Vice President, Global Head of Hospital Business and Biologics for Mylan Inc. (now Viatris Inc.). Earlier in his career, he held senior roles at Novartis Sandoz, Biogen, and Sanofi-Synthelabo.
He served as a director of Arch Biopartners from December 2016 until December 2019, and continued to support the Company as a Strategic Advisor thereafter. Dr. Vink?s appointment follows the retirement of Claude Allary from the Board of Directors. Mr. Allary has served as a director since 2014 and helped support Arch evolve into becoming a leading kidney therapeutics company, with two lead drug candidates currently in Phase II trials.
